Actively Recruiting
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
Led by Massachusetts General Hospital · Updated on 2026-03-13
50
Participants Needed
1
Research Sites
137 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this interventional study is to evaluate two strategies for how to provide intravenous (IV) fluids for treating patients with acute kidney injury (AKI) in cirrhosis. The main question it aims to answer is: what is the safety, efficacy, and feasibility of providing a recommendation to use a Volume Assessment Guidance Algorithm (VAGA) or give standard of care doses of IV albumin? Patients will be randomly assigned where their treating teams will receive a VAGA-based recommendation or a standard of care IV albumin recommendation.
CONDITIONS
Official Title
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult age 18 years or greater
- Signed informed consent form by the participant or legally authorized representative
- Currently admitted to the hospital
- Diagnosis of decompensated cirrhosis before or at admission
- Presence of acute kidney injury defined by specific criteria within the prior 7 days
You will not qualify if you...
- Requiring more than 2 liters of supplemental oxygen at screening
- In shock needing vasopressors (except certain vasoconstrictors allowed)
- Allergy or contraindication to IV albumin
- Expected death, liver transplant, or renal replacement therapy within 48 hours
- Unable to provide informed consent
- Hepatic encephalopathy grade 3 or 4 at screening
- Already received more than 200 grams of albumin during current admission
- Severe active bleeding requiring 3 or more blood transfusions in prior 48 hours
- Admitted to intensive care unit at screening
- On mechanical ventilation at screening
- New York Heart Association class 3 or 4 congestive heart failure symptoms
- History of prior liver or kidney transplant
- Pregnant or nursing
- Any condition that could interfere with safe completion of the study as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here